Outcome of COVID-19 patients with use of Tocilizumab: A single center experience

Muhammad Zain Mushtaq; Saad Bin Zafar Mahmood; Bushra Jamil; Adil Aziz; Syed Ahsan Ali

doi:10.1016/j.intimp.2020.106926

ScienceGate Book Chapters

JOURNAL ARTICLE

Outcome of COVID-19 patients with use of Tocilizumab: A single center experience

Muhammad Zain Mushtaq Saad Bin Zafar Mahmood Bushra Jamil Adil Aziz Syed Ahsan Ali

Year: 2020 Journal: International Immunopharmacology Vol: 88 Pages: 106926-106926 Publisher: Elsevier BV

DOI: 10.1016/j.intimp.2020.106926

Get Full-Text PDF Get Analytical Report

Keywords:

Tocilizumab Medicine Cytokine release syndrome ARDS Cytokine storm Internal medicine Adverse effect Interleukin 6 Coronavirus disease 2019 (COVID-19) Cytokine Lung Rheumatoid arthritis Disease

Metrics

Cited By

0.57

FWCI (Field Weighted Citation Impact)

Refs

0.79

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

COVID-19 Clinical Research Studies

Health Sciences → Medicine → Infectious Diseases

Long-Term Effects of COVID-19

Health Sciences → Medicine → Neurology

SARS-CoV-2 and COVID-19 Research

Health Sciences → Medicine → Infectious Diseases

Outcome of COVID-19 patients with use of Tocilizumab: A single center experience

Metrics

Citation History

Topics

Related Documents

Efficacy of Tocilizumab in COVID‐19: Single‐Center Experience

Tocilizumab treatment in COVID‐19: A single center experience

Outcome of COVID 19 in hemodialysis patients: single center experience

TOCILIZUMAB USE IN SEVERE COVID-19: A SINGLE CENTER EXPERIENCE

Tocilizumab Administration for COVID-19 Pneumonia: A Single Center Experience Description